Idis

Idis is a global leader in managed access programs, specializing in providing ethical access to medicines that are unlicensed or unavailable in specific geographic regions. Founded in 1987 and acquired by Clinigen Group in 2015, the company partners with pharmaceutical and biotechnology companies to implement Named Patient Programs and Compassionate Use programs. Their expertise lies in navigating complex regulatory environments to deliver life-saving treatments to patients with unmet medical needs, particularly in oncology and rare diseases. The company provides a vital link between drug developers and healthcare professionals, ensuring that patients can access critical therapies before they are commercially launched or when they are discontinued. Following its acquisition, Idis was integrated into Clinigen's Managed Access division, creating the world's largest provider of such services.